Drug General Information
Drug ID
D08TVU
Former ID
DIB019556
Drug Name
compound 5n
Drug Type
Small molecular drug
Indication Discovery agent Investigative [530930]
Structure
Download
2D MOL
Formula
C24H24ClF3N6
InChI
InChI=1S/C24H24ClF3N6/c25-19-1-2-20(24(26,27)28)18(11-19)15-34-10-7-31-23-21(34)12-17(14-32-23)16-3-4-30-22(13-16)33-8-5-29-6-9-33/h1-4,11-14,29H,5-10,15H2,(H,31,32)
InChIKey
AHZCYZMNFBGXAC-UHFFFAOYSA-N
PubChem Compound ID
PubChem Substance ID
Target and Pathway
Target(s) ALK tyrosine kinase receptor Target Info Inhibitor [530930]
doublecortin-like kinase 3 Target Info Inhibitor [543535]
Mitogen-activated protein kinasekinase kinase 3 Target Info Inhibitor [530930]
KEGG Pathway Non-small cell lung cancer
NetPath Pathway TSH Signaling Pathway
PANTHER Pathway B cell activation
EGF receptor signaling pathway
FGF signaling pathway
Pathway Interaction Database p38 MAPK signaling pathway
Regulation of p38-alpha and p38-beta
IL1-mediated signaling events
TNF receptor signaling pathway
Reactome Interleukin-1 signaling
WikiPathways Differentiation PathwayWP481:Insulin Signaling
EGF/EGFR Signaling Pathway
MAPK Cascade
Structural Pathway of Interleukin 1 (IL-1)
EBV LMP1 signaling
TNF alpha Signaling Pathway
IL-1 signaling pathway
Interleukin-1 signaling
References
Ref 530930Synthesis and structure-activity relationships of 1,2,3,4-tetrahydropyrido[2,3-b]pyrazines as potent and selective inhibitors of the anaplastic lymphoma kinase. Bioorg Med Chem. 2010 Jun 15;18(12):4351-62.
Ref 530930Synthesis and structure-activity relationships of 1,2,3,4-tetrahydropyrido[2,3-b]pyrazines as potent and selective inhibitors of the anaplastic lymphoma kinase. Bioorg Med Chem. 2010 Jun 15;18(12):4351-62.
Ref 543535(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2007).

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.